Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Non-comparative, Phase II Study Investigating the Best Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Sequence in Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) Harboring EGFR Mutations

NCT04811001 is registered in ClinicalTrials.gov with Fondazione Ricerca Traslazionale as lead sponsor.

NCT NCT04811001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04811001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Non-comparative, Phase II Study Investigating the Best Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Sequence in Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) Harboring EGFR Mutations
Lead sponsor
Fondazione Ricerca Traslazionale
Phase
Phase 2
Overall status
Unknown status
Start date
June 12, 2020
Completion date
December 31, 2023
Enrollment
170 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc